Abstract
An inflammatory condition known as arthritis affects one or more joints in the body. The pathophysiology of rheumatoid arthritis (RA), a diverse ailment with a complicated and still poorly known pathogenesis, involves many different cell types in the destruction of the joints. Due to this complexity, clinical course and severity vary widely amongst patients and genetic and/or environmental factors may also impact them. In addition to the conventional synthetic disease-modifying anti-rheumatic drugs, biologics have demonstrated efficacy and safety in symptomatic relief, reducing bone loss, and maintaining the function, which has considerably improved the treatment of rheumatoid arthritis. Since current drugs periodically fail, only substantially treat the ailment or have unfavorable side effects. There are still unmet treatment requirements in rheumatoid arthritis despite the availability of a wide range of therapeutic choices and their combinations. Unfortunately, the ‘nonresponse’ pathways are still not fully understood, although they most definitely have to do with the covert variability of the pathophysiology of the disease. In this research, we will narrate the current and upcoming biological treatments and their cellular aims.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
